Kawasaki Disease and Vaccination: Prospective Case-Control and Case-Crossover Studies among Infants in Japan

Kenji Murata 1, Sagano Onoyama 1,2, Kenichiro Yamamura 3, Yumi Mizuno 1, Kenji Furuno 1, Keita Matsubara 4, Ken Hatae 2, Kiminori Masuda 5, Yuichi Nomura 5, Takuro Ohno 6, Akiko Kinumaki 7, Masaru Miura 8, Yasunari Sakai 9, Shouichi Ogha 9, Wakaba Fukushima 10, Junji Kishimoto 11, Yosikazu Nakamura 12 and Toshiro Hara 1,*

1 Kawasaki Disease Center, Fukuoka Children’s Hospital, Fukuoka 813-0017, Japan; murata.k@fcho.jp (K.M.); sonyoama178@gmail.com (S.O.); mizuno.y@fcho.jp (Y.M.); furuno.k@fcho.jp (K.F.)
2 Department of Pediatrics, Japanese Red Cross Fukuoka Hospital, Fukuoka 815–8555, Japan; hatae.k@fukuoka-med.jrc.or.jp
3 Department of Perinatal and Pediatric Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812–8582, Japan; yamamura@pediatr.med.kyushu-u.ac.jp
4 Department of Pediatrics, Hiroshima City Funairi Citizens Hospital, Hiroshima 730–0844, Japan; keitamatsubara3@gmail.com
5 Department of Pediatrics, Kagoshima City Hospital, Kagoshima 890–8760, Japan; kominori1123@yahoo.co.jp (K.M.); uchiyuichi@gmail.com (Y.N.)
6 Department of Pediatrics, Oita Prefectural Hospital, Oita 870–8511, Japan; ohno55@yahoo.co.jp
7 Department of General Pediatrics, Tokyo Metropolitan Children’s Medical Center, Fuchu, Tokyo 183–8561, Japan; kinumaki-tyk@umin.ac.jp
8 Department of Cardiology, Tokyo Metropolitan Children’s Medical Center, Fuchu, Tokyo 183–8561, Japan; masaru10miura@gmail.com
9 Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812–8582, Japan; yasunari@med.kyushu-u.ac.jp (Y.S.); ohgas@pediatr.med.kyushu-u.ac.jp (S.O.)
10 Department of Public Health, Research Center for Infectious Disease Sciences, Osaka City University Graduate School of Medicine, Osaka City University, Osaka 558–8585, Japan; wakaba@med.osaka-cu.ac.jp
11 Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka 812–8582, Japan; j.kishii@digital.med.kyushu-u.ac.jp
12 Department of Public Health, Jichi Medical University, Shimotsuke 329–0048, Japan; nakamuyk@jichi.ac.jp
* Correspondence: hara.t@fcho.jp; Tel.: +81-92-682-7000

Abstract: The causal effects of vaccines on Kawasaki disease (KD) remain elusive. We aimed to examine the association between vaccines administered during infancy and the development of KD in Japan. We conducted a multicenter prospective case-control study using questionnaires and compared the vaccination status of infants (age: 6 weeks to 9 months) who developed KD (KD group; n = 102) and those who did not develop KD (non-KD group; n = 139). Next, we performed a case-crossover study of 98 cases in the KD group and compared the status of vaccinations between the case and control periods. We also compared the incidence of KD in children for each 5-year period before and after the addition of new vaccines (2012–2013) using data from the Nationwide Survey of KD. In the case-control study, the vaccination status of the KD and control groups did not differ to a statistically significant extent. In the analysis of data from the Nationwide Survey of KD, the incidence of KD in children of ages subject to frequent vaccination showed no significant increases in the latter five years, 2014–2018. Based on these prospective analyses, we confirmed that vaccination in early infancy did not affect the risk of KD.

Keywords: Kawasaki disease; vaccines; infant; case-control study; case-crossover study; Nationwide Survey of Kawasaki disease in Japan
1. Introduction

Kawasaki disease (KD) is an acute systemic vasculitis of unknown cause in childhood [1]. Coronary artery abnormalities develop in 15–25% of untreated children with KD, and the sequelae include giant coronary aneurysms and coronary artery stenosis, leading to myocardial infarction and death [2]. The clinical and epidemiological features support that the disease is induced by an infectious agent in genetically susceptible individuals [3–7]. Although numerous microbes have been proposed as etiologic agents of KD, few have been consistently associated with the illness [4]. Similarly, there have been reports of patients developing KD after receiving rotavirus vaccine, pneumococcal conjugate vaccine (PCV), hepatitis B virus (HBV) vaccine, diphtheria, pertussis, tetanus and inactivated poliovirus vaccine (DPT-IPV), Haemophilus influenzae type b (Hib) vaccine and Bacillus Calmette-Guérin (BCG) vaccine [8]. Among them, the rotavirus vaccine RotaTeq® was associated with a higher risk of KD in pre-marketing phase 3 clinical trials, and KD was then listed as one of the serious side effects of RotaTeq® in 2007 [9]. However, their causal effects have not been established [8] because (1) these studies did not always clarify the effect of confounding factors, (2) they did not compare cases and controls in the same region and study period, since KD often occurs in temporal and regional clusters [10], and (3) they did not always recruit patients prospectively.

In the present study, we performed a prospective case-control study that considered confounding factors to examine the association between the vaccines administered in infancy and the development of KD. We also employed a case-crossover study and analyzed data (obtained from the Nationwide Survey of KD) from the periods before and after the addition of new vaccines in Japan.

2. Materials and Methods

A multicenter study was conducted at seven participating institutions in Japan: Fukuoka Children’s Hospital, Hiroshima City Funairi Citizens Hospital, Japanese Red Cross Fukuoka Hospital, Kagoshima City Hospital, Oita Prefectural Hospital, Tokyo Metropolitan Children’s Medical Center, and Fukuoka Higashi Medical Center. This study was approved by the ethics committee at each institution. Written informed consent was obtained prior to registration from the parents or guardians of the subjects.

2.1. Case-Control Study
2.1.1. Study Design and Subjects

This multicenter prospective case-control study included infants of 6 weeks to 9 months of age who were admitted to the seven institutions with KD (case) or without KD (control) between 1 January 2017, and 30 June 2019. Since new vaccines (rotavirus, PCV13, and Hib) were added to the national vaccination schedule in 2012–2013 in Japan, and the incidence of KD continued to increase until 2018, the study population was set from 6 weeks to 9 months of age. KD was diagnosed according to the diagnostic guidelines for Kawasaki disease (5th revised edition) of Japan [11]. Cases included both complete KD (five or six of six major symptoms) and incomplete KD (four of six major symptoms with coronary artery aneurysm). Controls were selected from patients admitted to the same facility at the same time as the KD patients. The exclusion criteria for enrollment were as follows: (i) serious underlying diseases complicated by immunodeficiency, (ii) treatment with immunosuppressive drugs, such as steroids, for renal, autoimmune, hematologic, cardiac, neurological, or other diseases, (iii) a history of immunoglobulin use, and (iv) a history of hypersensitivity to vaccines or vaccine components.

The diagnoses on the admission of the control group were as follows: respiratory infection (n = 62; 44.6%), urinary tract infection (n = 44; 31.7%), skin and soft tissue infection (n = 7; 5.0%), intestinal infection (n = 3; 2.2%), bacteremia (n = 2; 1.4%), allergy (n = 5; 3.6%), infant hemangioma (n = 3; 2.2%), rash (n = 2; 1.4%), and other (n = 11; focus of unknown origin, viral myocarditis, West syndrome, benign infantile spasms,
afebrile convulsion, intussusception, Hirschsprung’s disease, poor feeding, poor weight gain, lactose intolerance, and apparent life-threatening events).

2.1.2. Questionnaires

Questionnaires were used to collect information from a subject’s physicians and parents. The questionnaire for physicians was filled out based on interviews, medical records, and the Maternal and Child Health Handbook. The questionnaire for physicians included data on age, sex, diagnosis, date of admission, date of onset, underlying disease, and vaccination history (Hib vaccine, PCV13, HBV vaccine, DPT-IPV, rotavirus vaccine, and BCG vaccine). A copy of the Maternal and Child Health Handbook was recommended for accurate confirmation of the vaccination history, which includes the status of vaccinations and the date of each vaccination. In KD cases, data were also collected on the date of the diagnosis, a number of major symptoms of KD, treatment (intravenous immunoglobulin [IVIG], aspirin, and others), IVIG response, results of blood examination on admission (percentage of neutrophils, platelet count, aspartate aminotransferase [AST], sodium, and C-reactive protein), and the echocardiographic findings of the coronary artery, including the diameters of the proximal right coronary artery (segment [seg.] (1), the left main trunk (seg. 5), and the left anterior descending artery (seg. 6). Coronary artery aneurysm was diagnosed based on the following findings: enlargement of the peripheral coronary arteries by more than 1.5 times, a maximum diameter of $\geq 3$ mm in patients of $< 5$ years of age, a maximum diameter of $\geq 4$ mm in patients of $> 5$ years of age, or Z score $\geq 2.5$, and apparent lumen irregularity [2,12].

The questionnaire for the patient’s parents included information on age, sex, diagnosis, date of admission, breastfeeding, baby food, history of allergic diseases (food allergy, atopic dermatitis, and bronchial asthma), symptoms of infection (fever, cough, rhinorrhea, vomiting, and diarrhea) within 2 months before hospitalization, antibiotic use within 2 months before hospitalization, number of family members living with the patient, number of siblings, family history of KD, housing style, and occupation of the parents (based on the Japan Standard Occupational Classification [4th revision in December 1997]: (1) specialist and technical workers; (2) administrative and managerial workers; (3) clerical worker; (4) sales worker; (5) service worker; (6) security worker; (7) agriculture, forestry and fishery worker; (8) transport and communication worker; (9) production process and related worker; (10) workers not classifiable by occupation or unemployment [including homemaker]) [13].

2.1.3. Statistical Analyses

Continuous variables were tested for normality using the Shapiro-Wilk test. Comparison between the two groups was performed using the Wilcoxon rank-sum test because some variables were not normally distributed. The differences in categorical variables were compared between the two groups using Fisher’s exact test. The classifications of the parents’ occupations were compared between the two groups using Pearson’s chi-squared test. A univariate logistic regression analysis was used to examine the association between each vaccine and the development of KD and to calculate crude odds ratios. A conditional logistic regression analysis was performed for each vaccination with 10 fixed variables (age, sex, breastfeeding, baby food, history of allergic disease, symptoms of infection within 2 months before hospitalization, antibiotic use within 2 months before hospitalization, siblings, family history of KD, and housing style). $p$ values of $< 0.05$ were considered to indicate statistical significance. Statistical analyses were performed using JMP® Pro version 14.0 (SAS Institute, Cary, NC, USA) and SAS (version 9.4, SAS Institute Inc., Cary, NC, USA).
2.2. Case-Crossover Study

We performed a case-crossover study, an analytical method used to assess the changes in risk associated with transient exposure. This is a type of self-controlled study [14,15], and each subject is under his or her own control.

The subjects of the case-crossover study were patients in the KD group of the case-control study for whom the date of the onset of KD and the date of vaccination was known. Because all subjects in the KD group were >2 months of age, the observation period was 56 days (8 weeks) before the onset of KD.

In studies on KD in siblings [16–18], the interval of the onset of KD in two sibling patients peaked on the same day and at less than a week to one month, suggesting the involvement of a KD trigger that mostly occurred within a 7-day incubation period and occasionally occurred within a 28-day incubation period. We, therefore, defined the “case period” as 7 days (S) or 28 days (L) before the date of the onset of KD. In contrast, the “control period” was defined as 29–35 days (S) or 29–56 days (L) before the onset of KD, which was considered to be less associated with the development of KD (Figure 1a).

To compare the status of vaccinations in the case and control periods, we created a table that contained the number of vaccinations and person-time per subject (Figure 1b). To estimate the risk of developing KD in association with vaccination, we calculated the Mantel–Haenszel incidence ratio (IRMH) as the pooled estimate and its 95% confidence interval (95% CI) [14,15].

![Figure 1. Period setting and the analysis of the case-crossover study. (a) Definition of the case and control periods. Case periods were defined as the 7 days (S) or 28 days (L) before the date of the onset of KD. Control periods were defined as 29 to 35 days (S) or 29 to 56 days (L) prior to the onset of KD. (b) A table contained the vaccination status and person-time per subject (indicating as stratum “i”) to calculate the Mantel-Haenszel incidence ratio (IR_{MH}) as the pooled estimate.](image-url)

2.3. The Analysis of Data from the Nationwide Survey of KD in Japan

The Nationwide Survey of KD in Japan is conducted every two years, and the results are open to the public [19–24]. These include data on the number and incidence of KD patients by age group (per 100,000 children of 0–4 years of age per year in the vital statistics data for Japan) but do not include information on vaccines. In Japan, two types of rotavirus vaccines were released in November 2011 and July 2012. In 2013, the Hib vaccine and PCV13 were added to the National Immunization Program. Therefore, using Student’s t-test, we compared the number of KD patients and the incidence of KD in all ages and cases grouped by age (0–2 months, 3–5 months, 6–8 months, 9–11 months, and < 1 year) in the 5-year periods before and after 2012–2013.

3. Results

3.1. Case-Control Study

3.1.1. Patient Characteristics

The subjects included 241 patients (KD group, \( n = 102 \); control group, \( n = 139 \)) from seven participating institutions who met the enrollment criteria. Questionnaires could be collected from the subject’s physician and parents in all cases. Eighteen patients (KD group,
n = 8; control group, n = 10) had some missing data in the questionnaire items (Table 1), but vaccination history was collected without missing data from all 241 patients. The patients in the KD group (median age, 6 months; range: 2–9; standard deviation [SD]: 2.2) were significantly older than those in the control group (median age, 5 months; range, 1–9; SD, 2.3) (p = 0.017) (Table 1). There were 64 boys (62.7%) in the KD group and 77 boys (55.4%) in the control group; the proportions of patients of each sex did not differ between the two groups to a statistically significant extent (p = 0.29). The clinical features and laboratory results in the KD group are shown in Supplementary Table S1.

Table 1. Comparison of the background characteristics of the KD patients and controls.

| Characteristics                          | KD (n) | Control (n) | p    |
|------------------------------------------|--------|-------------|------|
| Age (months)                             | 6 (2–9) | 5 (1–9) | 0.017 2 |
| Sex (male)                               | 64 (62.7%) | 77 (55.4%) | 0.29 3 |
| Breast feeding                           | 94 (93.1%) | 120 (87.6%) | 0.20 3 |
| Baby food                                | 44 (43.6%) | 37 (27.0%) | 0.0088 3 |
| History of allergic disease              | 5 (5.0%) | 18 (13.0%) | 0.046 3 |
| Food allergy                             | 2 (2.0%) | 9 (6.5%) | 0.13 3 |
| Atopic dermatitis                        | 3 (3.0%) | 10 (7.3%) | 0.25 3 |
| Asthma                                   | 0 (0%) | 5 (3.6%) | 0.076 3 |
| Symptoms of infection within 2 months before hospitalization | 29 (29.0%) | 44 (32.1%) | 0.70 3 |
| Antibiotic use within 2 months before hospitalization | 16 (15.7%) | 21 (15.1%) | 1.00 3 |
| Number of family member living together  | 4 (3–11) | 4 (1–10) | 0.28 2 |
| Sibling(s)                               | 57 (55.9%) | 84 (60.9%) | 0.51 3 |
| Family history of KD                     | 6 (6.2%) | 10 (7.3%) | 0.80 3 |
| Housing style (detached house)           | 33 (32.7%) | 37 (27.6%) | 0.47 3 |

KD, Kawasaki disease. 1: Median (range), 2: Wilcoxon rank-sum test, 3: Fisher’s exact test.

With regard to the patient background factors, which were determined based on the questionnaires, the proportion of patients in whom baby food feeding had been initiated in the KD group was significantly higher than that in the control group in the univariate analysis; however, the association did not remain statistically significant in the multivariable analysis (Table 1, Supplementary Table S2). The proportion of patients with an allergic disease was significantly lower in the KD group; however, there was no difference in the proportions of patients with each allergic disease (Table 1). The proportions of patients who were breast feeding, patients with a history of infection or antimicrobial therapy, patients with a family history of KD, and patients with a detached house, and the number of siblings or family members living together did not differ between the two groups to a statistically significant extent. Furthermore, there were no significant differences between the two groups in the classifications of the parents’ occupations (fathers’ occupation, p = 0.475; mothers’ occupation, p = 0.732).

3.1.2. Comparison of Vaccination Status

The vaccination status for each of the six vaccines and their combinations administered in infancy were compared between the KD and control groups in univariate analysis (Table 2). There were no significant differences between the two groups in the vaccination status of any vaccine or the combination of all vaccines, three alum-containing vaccines, and three non-alum-containing vaccines.
Table 2. Comparison of the vaccination status by univariate and multivariable analyses.

| Vaccines                      | KD (n = 102) | Control (n = 139) | Univariate Analysis | Multivariable Analysis |
|-------------------------------|--------------|------------------|---------------------|------------------------|
|                               |              |                  | Crude OR (95%CI)    | Adjusted OR (95%CI)    |
|                               |              |                  | p                   | p                      |
| Vaccines with alum adjuvants  |              |                  |                     |                        |
| PCV13                         | 92 (90.2%)   | 115 (82.7%)      | 1.92 (0.87–4.22)    | 0.98 (0.32–2.95)       |
| HBV vaccine                   | 89 (87.3%)   | 110 (79.1%)      | 1.80 (0.89–3.68)    | 0.78 (0.28–2.17)       |
| DPT-IPV                       | 75 (73.5%)   | 98 (70.5%)       | 1.16 (0.65–2.06)    | 0.39 (0.14–1.09)       |
| Vaccines without alum adjuvants|              |                  |                     |                        |
| Hib vaccine                   | 93 (91.2%)   | 115 (82.7%)      | 2.15 (0.95–4.86)    | 1.19 (0.37–3.85)       |
| Rotavirus vaccine             | 64 (62.7%)   | 74 (53.2%)       | 1.47 (0.88–2.49)    | 1.32 (0.62–2.77)       |
| BCG vaccine                   | 48 (47.1%)   | 48 (34.5%)       | 1.68 (0.99–2.84)    | 0.58 (0.17–1.96)       |

The univariate analysis was performed using univariate logistic regression analysis. The multivariable analysis was performed using conditional logistic regression analysis. KD: Kawasaki disease, OR: Odds ratio, 95%CI: 95% confidence interval, PCV13: 13-valent pneumococcal conjugate vaccine, HBV: Hepatitis B virus, DPT-IPV: Diphtheria, pertussis, tetanus and inactivated poliovirus vaccine, Hib: Haemophilus influenzae type b, BCG: Bacillus Calmette-Guérin.

A conditional logistic regression analysis was performed with each vaccination and the following fixed variables: age (months), sex, breastfeeding, baby food, history of allergic disease, symptoms of infection within 2 months before hospitalization, antibiotic administration within 2 months before hospitalization, sibling(s), family history of KD, or housing style (Supplementary Table S2). We evaluated the odds ratios and their 95% CIs for the development of KD with each vaccine and found no significant association between vaccination and KD development (Table 2).

3.2. Case-Crossover Study

The dates of onset and vaccination were fully available for 98 of 102 cases in the KD group. Thus, these 98 cases were further subjected to the case-crossover study (Figure 1). Table 3 shows the number of vaccinated individuals, the IR<sub>MH</sub>, and 95% CIs for each vaccine in the case and control periods. With a case and control period of 7 days (S), we did not find evidence that vaccination was significantly more frequent in the case period. On the other hand, with a period of 28 days (L), the number of patients who received BCG vaccination was significantly lower in the case period (IR<sub>MH</sub> 0.41 [0.17–0.99]). For other vaccines, no significant differences were observed between the case and control periods (Table 3). Since this analysis included multiple doses of the same vaccine, we also limited the analysis to the first dose of each vaccine and found similar results (Supplementary Table S3).

Table 3. Case-crossover study on vaccination in patients with KD.

| Vaccines                      | Number of Subjects Who Received Vaccine in the Case Period | Number of Subjects Who Received Vaccine in the Control Period | IR<sub>MH</sub> (95%CI) |
|-------------------------------|----------------------------------------------------------|-------------------------------------------------------------|--------------------------|
| (S) 7 days                    |                                                          |                                                             |                          |
| PCV13                         | 9                                                        | 9                                                           | 1.00 (0.40–2.52)         |
| HBV vaccine                   | 7                                                        | 6                                                           | 1.17 (0.39–3.47)         |
| DPT-IPV                       | 7                                                        | 5                                                           | 1.40 (0.44–4.41)         |
| Hib vaccine                   | 9                                                        | 8                                                           | 1.13 (0.43–2.92)         |
| Rotavirus vaccine             | 4                                                        | 2                                                           | 2.00 (0.37–10.92)        |
| BCG vaccine                   | 2                                                        | 3                                                           | 0.67 (0.11–3.99)         |
| (L) 28 days                   |                                                          |                                                             |                          |
| PCV13                         | 29                                                       | 33                                                          | 0.88 (0.53–1.45)         |
| HBV vaccine                   | 24                                                       | 27                                                          | 0.89 (0.51–1.54)         |
| DPT-IPV                       | 20                                                       | 30                                                          | 0.67 (0.37–1.17)         |
| Hib vaccine                   | 29                                                       | 33                                                          | 0.88 (0.53–1.45)         |
| Rotavirus vaccine             | 15                                                       | 23                                                          | 0.65 (0.34–1.25)         |
| BCG vaccine                   | 7                                                        | 17                                                          | 0.41 (0.17–0.99)         |

IR<sub>MH</sub>: Mantel-Haenszel incidence ratio, 95%CI: 95% confidence interval, PCV13: 13-valent pneumococcal conjugate vaccine, HBV: Hepatitis B virus, DPT-IPV: Diphtheria, pertussis, tetanus and inactivated poliovirus vaccine, Hib: Haemophilus influenzae type b, BCG: Bacillus Calmette-Guérin.
3.3. The Analysis of Data from the Nationwide Survey of KD in Japan

In 2012–2013, new vaccines (PCV13, Hib, and rotavirus) were added to the national vaccination schedule in Japan. Therefore, from the data of the Nationwide Survey of KD in Japan, we compared the number of patients with KD and the incidence rate of KD by age group in the first 5-year period (2007–2011) and the second 5-year period (2014–2018) (Table 4). For all ages, both the number of patients and incidence of KD were significantly higher in 2014–2018 than in 2007–2011. However, the number of KD patients younger than one year of age did not differ between the two periods. Notably, when the new vaccines were administered at 3–5 months of age, the number of cases was significantly lower in the years 2014–2018. The incidence rate at 3–5 months of age tended to be lower in 2014–2018, although it did not reach statistical significance (Table 4).

Table 4. The number of KD patients and incidence of KD by age group for the 5-year periods before and after 2012–2013 according to the Nationwide Survey of KD.

| Age Group      | 2007–2011 | 2014–2018 | p      |
|----------------|-----------|-----------|--------|
| Total of all ages | 11,970 (775) | 16,020 (375) | <0.0001 |
| <1 year old    | 3073 (180) | 3161 (111) | 0.38   |
| 0–2 months     | 235 (9)    | 240 (9)   | 0.68   |
| 3–5 months     | 839 (52)   | 702 (13)  | 0.0004 |
| 6–8 months     | 997 (66)   | 1013 (57) | 0.70   |
| 9–11 months    | 1001 (86)  | 1206 (62) | 0.0025 |
| Incidence rate 1 | 224.6 (16.0) | 324.0 (21.6) | <0.0001 |
| Total of all ages | 87.8 (7.0)  | 99.9 (9.1) | 0.046  |
| 3–5 months     | 313.4 (21.9)| 291.4 (10.8)| 0.078  |
| 6–8 months     | 372.0 (24.6)| 420.6 (28.6)| 0.021  |
| 9–11 months    | 373.8 (32.2)| 500.6 (20.7)| <0.0001 |

Table 4: The number of KD patients and incidence of KD by age group for the 5-year periods before and after 2012–2013 according to the Nationwide Survey of KD.

Mean (standard deviation). 1: Based on the population data in Vital Statistics of Japan per 100,000 populations per year.

The recommended period for vaccination among infants in Japan: 13-valent pneumococcal conjugate vaccine, 2–5 months (three doses); Hepatitis B virus vaccine, 2–3 months (first and second doses) and 7–11 months (third dose); Diphtheria, pertussis, tetanus and inactivated poliovirus vaccine, 3–5 months (three doses); Haemophilus influenzae type b vaccine, 2–5 months (three doses); Rotavirus vaccine, 2–4.5 months (monovalent, two doses) or 2–6.5 months (pentavalent, three doses); Bacillus Calmette-Guérin vaccine, 5–7 months (one dose).

4. Discussion

We have performed a case-control study considering confounding factors and a case-crossover study by analyzing the Nationwide Survey of KD. These results have shown no association between vaccination in early infancy and the development of KD.

According to an analysis of Adverse Events Following Immunization for both rotavirus vaccines based on the US Vaccine Adverse Events Reporting System (VAERS) and VigiBase, the WHO global database of Individual Case Safety Reports, the reporting odds ratio for KD was 14.61 (95% CI: 10.96–19.49) for VAERS and 5.57 (95% CI: 3.90–7.94) for VigiBase, suggesting the high association of rotavirus vaccine with KD [25]. On the other hand, a cohort study by Layton et al. [26] showed that the relative risk of developing KD in infants who received rotavirus vaccine (Rotarix® or RotaTeq®) was 0.54 (95% CI 0.20–1.48), and there was no association between vaccination and KD development. In a meta-analysis of multiple cohort studies and RCTs, the incidence of KD was low, at 24 cases per 100,000 (95% CI: 11.98–48.26), and the relative risk of the prevalence rate was 1.55 (95% CI: 0.41–5.93), with no significant association [27].

Regarding PCV13, the relative incidence of complete KD after one dose of PCV13 was 2.59 (95% CI 1.16–5.81), which was statistically significant [28]. However, there was
no significant increase in KD development after dose 2 or 3 [28]. On the other hand, the relative risk of developing KD within 28 days of vaccination with PCV13 was 2.38 (95% CI 0.92–6.38), which was not statistically significant [29]. As for the multicomponent meningococcal serogroup B (4CMenB) vaccine, the estimated incidence of KD was 72 (95% CI: 23–169) per 100,000 subject-years in the 4CMenB vaccinated group and 56 (95% CI: 1–311) in the control group, which was similar in both groups [30]. Furthermore, a systematic review of the association of various vaccinations with KD showed no evidence that vaccination increased the risk of developing KD, including the PCV13, rotavirus, and 4CMenB vaccines [31].

There are several reports that have examined the association between vaccination and the incidence of KD using self-controlled studies. Abrams et al. [32] reported that the rate of vaccination (DTaP; inactivated poliovirus; seven-valent PCV; measles, mumps and rubella, HBV; and Hib) in the 42 days before the onset of KD was significantly lower than that in the 43–84 days before the onset (control period) (rate ratio 0.79, 95% CI: 0.64–0.97). Stowe et al. [33] reported that, based on the self-controlled case-series method examining the cases in which KD developed within 28 days of vaccination, the relative incidence (RI) was 0.51 (95% CI: 0.34–0.78) for the PCV vaccine and 1.03 (95% CI: 0.54–1.98) for the meningococcal B vaccine; thus, there was no evidence that these vaccines increased the risk of KD.

Elevated serum levels of cell death-related molecules, such as S100 proteins, high mobility group box-1 protein, heat shock proteins, and oxidized phospholipids, are among the characteristics in patients with the acute phase of KD [34–40]. Patients with Yersinia pseudotuberculosis infection and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection reproducibly develop principal KD symptoms fulfilling the diagnostic criteria for KD [41,42]. The induction of apoptosis and pyroptosis of endothelial cells or macrophages have been observed in patients with Yersinia infection [43] and coronavirus disease 2019 [44]. Pyroptosis during infection with Yersinia and SARS-CoV-2 releases proinflammatory cellular contents, such as damage-associated molecular patterns (DAMPs). Reactive oxygen species (ROS) immediately oxidize the membrane phospholipids of the damaged cells [45]. DAMPs, including oxidized phospholipids and low-density lipoproteins, activate the endothelial and innate immune cells to further produce proinflammatory cytokines and ROS [46]. These processes induce the activation of the NACHT, LRR, and PYD domains-containing protein 3 (NLRP3) inflammasomes, resulting in the acceleration of pyroptosis of the endothelial cells and monocytes [47]. Thus, proinflammatory cell death (pyroptosis) of endothelial and innate immune cells appears to play a critical role in developing KD vasculitis.

Vaccines include live-attenuated and non-live composite ones (Supplementary Table S4). There is no evidence of cell death associated with rotavirus vaccine (a live attenuated vaccine) or non-live Hib conjugate vaccine containing no aluminum adjuvant [48]. BCG vaccine induces the local cell death (apoptosis) of macrophages; however, BCG substrain Tokyo must have the minimum effect since it is considered the safest BCG vaccine [49,50]. With regard to non-live composite vaccines, aluminum adjuvant-containing vaccines (PCV13, DPT-IPV, and HBV vaccine) can be associated with local cell death (necrosis) at the injection site [51]. The local cell death can lead to the limited release of DAMPs (host cell components such as DNA and cell membrane). Thus, in the absence of massive proinflammatory cell death (pyroptosis) of endothelial cells and the subsequent release of excessive DAMPs, it is likely that vaccines make little contribution to the development of KD [37,52].

The present study was associated with some limitations. First, in the prospective case-control study, the numbers of patients and controls enrolled were relatively small. In addition, it was not possible to match the age and sex of the two groups perfectly. However, the timing of enrollment of the cases and the corresponding controls at each institution were almost identical. It was possible to statistically analyze the association between vaccination and KD development in the two groups by adjusting for confounding factors using multivariable analysis. Second, we conducted an epidemiological evaluation
of vaccination and KD development based on questionnaires; however, we did not perform an immunological evaluation of the patients. Finally, in the case-crossover study, the long observation period was set at 8 weeks. In patients with KD at 2–3 months of age, in the control period (day -56 to -28), there were fewer opportunities to receive vaccinations than the case period. However, despite this situation, the number of vaccinations that patients with KD received in the case period did not differ from that in the control period to a statistically significant extent, which supported the present results.

5. Conclusions

The case-control and case-crossover studies, with the analysis of the data of the Nationwide Survey of KD, demonstrated that there was no association between vaccination in early infancy and the development of KD. Further studies of larger study populations will be useful for confirming the findings of the present study.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/vaccines9080839/s1. Table S1: Clinical features of patients with Kawasaki disease. Table S2: Multivariable analysis with fixed variables of patient backgrounds and each vaccine. Table S3: Case-crossover study limited to the first dose of each vaccine. Table S4: Vaccines, adjuvants, and corresponding pattern recognition receptors.

Author Contributions: Conceptualization, S.O. (Sagano Onoyama), Y.M., K.F., and T.H.; methodology, K.M. (Kenji Murata), S.O. (Sagano Onoyama), Y.M., K.F., W.F., Y.N. (Yosikazu Nakamura), and T.H.; software, none; validation, Y.N. (Yosikazu Nakamura) and T.H.; formal analysis, K.M. (Kenji Murata), W.F., J.K., and Y.N. (Yosikazu Nakamura); investigation, K.M. (Kenji Murata), S.O. (Sagano Onoyama), K.M. (Keita Matsubara), K.H., K.M. (Kiminori Masuda), Y.N. (Yuichi Nomura) T.O., A.K., and M.M.; resources, S.O. (Sagano Onoyama), Y.M. and K.F.; data curation, K.M. (Kenji Murata), S.O. (Sagano Onoyama) and T.H.; writing—original draft preparation, K.M. (Kenji Murata); writing—review and editing, K.Y., Y.M., Y.S., S.O. (Shouichi Ohga), W.F., Y.N. (Yosikazu Nakamura), and T.H.; visualization, K.M. (Kenji Murata), K.Y. and T.H.; supervision, T.H.; project administration, K.M. (Kenji Murata), S.O. (Sagano Onoyama), Y.M. and K.F.; funding acquisition, S.O. (Sagano Onoyama) and Y.M.; All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by a Fukuoka Children’s Hospital Research Grant.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and was approved by the Institutional Ethics Committee of Fukuoka Children’s Hospital (protocol code: 28–47, date of approval: 6 January 2017).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data published in this study are available upon request to the corresponding author. This data has not been made public to protect privacy.

Acknowledgments: We thank Manao Nishimura, Takuya Oda, Yasutaka Nakashima, Yui Takada, and Eiji Kubo (Department of Pediatrics, Japanese Red Cross Fukuoka Hospital), Takuya Harada (Department of Pediatrics, Oita Prefectural Hospital), and Kotomi Chikama and Naohiro Suga (Department of Pediatrics, National Hospital Organization Fukuoka Higashi Medical Center) for providing detailed information of the patients through the questionnaire and asking the patient’s parents to complete the questionnaire. We also thank Hiroko Watanabe (Center for Clinical and Translational Research, Kyushu University Hospital) for supporting the statistical analysis. We appreciate the help of Brian Quinn (Japan Medical Communication, Fukuoka, Japan) in editing the manuscript.

Conflicts of Interest: The authors declare no conflict of interest in association with the present study.

References

1. Kawasaki, T.; Kosaki, F.; Okawa, S.; Shigematsu, I.; Yanagawa, H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. *Pediatrics* 1974, 54, 271–276.
2. Fukazawa, R.; Kobayashi, J.; Ayusawa, M.; Hamada, H.; Miura, M.; Mitani, Y.; Tsuda, E.; Nakajima, H.; Matsuura, H.; Ikeda, K.; et al. JCS/JSCS 2020 Guideline on Diagnosis and Management of Cardiovascular Sequelae in Kawasaki Disease. *Circ. J.* 2020, 84, 1348–1407. [CrossRef] [PubMed]

3. Jamieson, N.; Singh-Grewal, D. Kawasaki Disease: A Clinician’s Update. *Int. J. Pediatrics* 2013, 2013, 645391. [CrossRef] [PubMed]

4. Haraguchi, T.; Nakashima, Y.; Sakai, Y.; Nishio, H.; Motomura, Y.; Yamasaki, S. Kawasaki disease: a matter of innate immunity. *Clin Exp Immunol.* 2016, [CrossRef] [PubMed]

5. Rowley, A.H.; Baker, S.C.; Orenstein, J.M.; Shulman, S.T. Searching for the cause of Kawasaki disease–cytoplasmic inclusion bodies provide new insight. *Nat. Rev. Microbiol.* 2008, 6, 394–401. [CrossRef]

6. Matsuno, S.; Utagawa, E.; Sugitani, A. Association of rotavirus infection with Kawasaki syndrome. *J. Infect. Dis.* 1983, 148, 177. [CrossRef] [PubMed]

7. Chang, L.Y.; Lu, C.Y.; Shao, P.L.; Lee, P.I.; Lin, M.T.; Fan, T.Y.; Cheng, A.L.; Lee, W.L.; Hu, J.J.; Yeh, S.J.; et al. Viral infections and Kawasaki Disease in San Diego County suggest environmental triggers. *Sci. Rep.* 2018, 8, 16140. [CrossRef]

8. Ayusawa, M.; Sonobe, T.; Uemura, S.; Ogawa, S.; Nakamura, Y.; Kiyosawa, N.; Ishii, M.; Harada, K. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). *Pediatr. Int.* 2005, 47, 232–234. [CrossRef]

9. Kobayashi, T.; Ayusawa, M.; Suzuki, H.; Abe, J.; Ito, S.; Kato, T.; Kamada, M.; Shiono, J.; Suda, K.; Tsuchiya, K.; et al. Revision of diagnostic guidelines for Kawasaki disease (6th revised edition). *Pediatr. Int.* 2020, 62, 1135–1138. [CrossRef]

10. Ministry of Internal Affairs and Communications of Japan. Japan Standard Occupational Classification (Rev. 4th, December 1997), Classification Structure and Explanatory Notes. Available online: https://www.soumu.go.jp/english/dgpp_ss/seido/shokgyou/ssoc.htm (accessed on 19 March 2021).

11. Fukushima, W.; Ozasa, K.; Okumura, A.; Mori, M.; Hosoya, M.; Nakano, T.; Tanabe, T.; Yamaguchi, N.; Suzuki, H.; Mori, M.; et al. Oseltamivir use and severe abnormal behavior in Japanese children and adolescents with influenza: Is a self-controlled case series study applicable? *Vaccine* 2017, 35, 4817–4824. [CrossRef]

12. Kim, M.; Park, T.; Yi, S.G.; Oh, J.K.; Choi, B. Risk assessment for Kawasaki disease in children using a case-control study. *Am. J. Epidemiol.* 2003, 157, 158–165. [CrossRef] [PubMed]

13. Fujita, Y.; Nakamura, Y.; Sakata, K.; Haraguchi, T.; Kobayashi, M.; Nagai, M.; Yanagawa, H.; Kawasaki, T. Kawasaki Disease in Families. *Pediatrics* 1989, 84, 666–669.

14. Yanagawa, H.; Nakamura, Y.; Yashiro, M.; Fujita, Y.; Nagai, M.; Kawasaki, T.; Aso, S.; Imada, Y.; Shigematsu, I. A Nationwide Incidence Survey of Kawasaki Disease in 1985–1986 in Japan. *J. Infect. Dis.* 1988, 158, 1296–1301. [CrossRef]

15. Banday, A.Z.; Bhattacharya, D.; Pandiarajan, V.; Singh, S. Kawasaki disease in siblings in close temporal proximity to each other: What are the implications? *Clin. Rheumatol.* 2021, 40, 849–855. [CrossRef]

16. Nakamura, Y.; Yashiro, M.; Uehara, R.; Sadakane, A.; Chihiara, I.; Aoyama, Y.; Kotani, K.; Yanagawa, H. Epidemiologic features of Kawasaki disease in Japan: results of the 2007–2008 nationwide survey. *J. Epidemiol./jpn. Epidemiol. Assoc.* 2010, 20, 302–307. [CrossRef] [PubMed]

17. Nakamura, Y.; Yashiro, M.; Uehara, R.; Sadakane, A.; Tsuboi, S.; Aoyama, Y.; Kotani, K.; Tsogolzolbatar, E.O.; Yanagawa, H. Epidemiologic features of Kawasaki disease in Japan: results of the 2009–2010 nationwide survey. *J. Epidemiol./jpn. Epidemiol. Assoc.* 2012, 22, 216–221. [CrossRef]

18. Makino, N.; Nakamura, Y.; Yashiro, M.; Ae, R.; Tsuboi, S.; Aoyama, Y.; Kojo, T.; Uehara, R.; Kotani, K.; Yanagawa, H. Descriptive epidemiology of Kawasaki disease in Japan, 2011–2012: from the results of the 22nd nationwide survey. *J. Epidemiol./jpn. Epidemiol. Assoc.* 2015, 25, 239–245. [CrossRef] [PubMed]

19. Makino, N.; Nakamura, Y.; Yashiro, M.; Sano, T.; Ae, R.; Kosami, K.; Kojo, T.; Aoyama, Y.; Kotani, K.; Yanagawa, H. Epidemiological observations of Kawasaki disease in Japan, 2013–2014. *Pediatr. Int.* 2018, 60, 581–587. [CrossRef] [PubMed]

20. Makino, N.; Nakamura, Y.; Yashiro, M.; Kosami, K.; Matsubara, Y.; Ae, R.; Aoyama, Y.; Yanagawa, H. Nationwide epidemiologic survey of Kawasaki disease in Japan, 2015–2016. *Pediatr. Int.* 2019, 61, 397–403. [CrossRef] [PubMed]

21. Ae, R.; Makino, N.; Kosami, K.; Kuwabara, M.; Matsubara, Y.; Nakamura, Y. Epidemiology, Treatments, and Cardiac Complications in Patients with Kawasaki Disease: The Nationwide Survey in Japan, 2017–2018. *J. Pediatr.* 2020, 225, 23–29. [CrossRef] [PubMed]

22. Bonaldo, G.; Noseda, R.; Ceschi, A.; Vaccheri, A.; Motola, D. Evaluation of the safety profile of rotavirus vaccines: a pharmacovigilance analysis on American and European data. *Sci. Rep.* 2020, 10, 13601. [CrossRef] [PubMed]

23. Layton, J.B.; Butler, A.M.; Panozzo, C.A.; Brookhart, M.A. Rotavirus vaccination and short-term risk of adverse events in US infants. *Paediatr. Perinat. Epidemiol.* 2018, 32, 448–457. [CrossRef] [PubMed]

24. Mellon, N.G.; Silva, M.T.; Paglia, M.D.G.; Lopes, L.C.; Barberato-Filho, S.; Del Fiol, F.S.; Bergamaschi, C.C. Kawasaki Disease and the Use of the Rotavirus Vaccine in Children: A Systematic Review and Meta-Analysis. *Front. Pharm.* 2019, 10, 1075. [CrossRef]
28. Yung, C.F.; Ma, X.; Cheung, Y.B.; Oh, B.K.; Soh, S.; Thoon, K.C. Kawasaki Disease following administration of 13-valent pneumococcal conjugate vaccine in young children. Sci. Rep. 2019, 9, 14705. [CrossRef]

29. Baker, M.A.; Baer, B.; Kulldorff, M.; Zichittlella, L.; Reindel, R.; DeLucia, S.; Lipowicz, H.; Freitas, K.; Jin, R.; Yih, W.K. Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young children: A self-controlled risk interval and cohort study with null results. PloS Med. 2019, 16, e1002844. [CrossRef]

30. O’Ryan, M.; Stoddard, J.; Toneatto, D.; Wassil, J.; Dull, P.M. A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program. Drugs 2014, 74, 15–30. [CrossRef] [PubMed]

31. Phuong, L.K.; Bonetto, C.; Butterly, J.; Fernus, Y.B.; Chandler, R.; Felicetti, P.; Goldenthal, K.L.; Kucuku, M.; Monaco, G.; Pahud, B.; et al. Kawasaki disease and immunisation: A systematic review. Vaccine 2017, 35, 1770–1779. [CrossRef] [PubMed]

32. Abrams, J.Y.; Weintraub, E.S.; Baggs, J.M.; McCarthy, N.L.; Belongia, E.A.; Jackson, M.L.; Naleway, A.L.; et al. Childhood vaccines and Kawasaki disease, Vaccine Safety Datalink, 1996–2006. Vaccine 2015, 33, 382–387. [CrossRef]

33. Stowe, J.; Andrews, N.J.; Turner, P.J.; Miller, E. The risk of Kawasaki disease after pneumococcal conjugate & meningococcal B vaccine in England: A self-controlled case-series analysis. Vaccine 2020, 38, 4935–4939. [CrossRef] [PubMed]

34. Abe, J.; Jibiki, T.; Noma, S.; Nakajima, T.; Saito, H.; Terai, M. Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J. Immunol. 2005, 174, 5837–5845. [CrossRef]

35. Foell, D.; Ichida, F.; Vogl, T.; Yu, X.; Chen, R.; Miyawaki, T.; Sorg, C.; Roth, J. S100A12 (EN-RAGE) in monitoring Kawasaki disease. J. Immunol. 2010, 184, 361–1270–1272. [CrossRef]

36. Hoshina, T.; Kusuhara, K.; Ikeda, K.; Mizuno, Y.; Saito, M.; Harra, T. High mobility group box 1 (HMGB1) and macrophage migration inhibitory factor (MIP) in Kawasaki disease. Scand. J. Rheumatol. 2008, 37, 445–449. [CrossRef]

37. Jia, C.; Zhang, J.; Chen, H.; Zhuo, Y.; Chen, H.; Qian, F.; Zhou, K.; Niu, C.; Wang, F.; Qu, H.; et al. Endothelial cell pyroptosis plays an important role in Kawasaki disease via HMGB1/RAGE/cathepsin B signaling pathway and NLRP3 inflammasome activation. Cell Death Dis. 2019, 10, 778. [CrossRef]

38. Nakashima, Y.; Sakai, Y.; Mizuno, Y.; Furuno, K.; Hirono, K.; Takatsuki, S.; Suzuki, H.; Onouchi, Y.; Kobayashi, T.; Tanabe, K.; et al. Lipidomics links oxidized phosphatidylcholines and coronary arteries in Kawasaki disease. Cardiovasc. Res. 2021, 117, 96–108. [CrossRef] [PubMed]

39. Takeshita, S.; Kawase, H.; Yamamoto, M.; Fujisawa, T.; Sekine, I.; Yoshioha, S. Increased expression of human 63-KD heat shock protein gene in Kawasaki disease determined by quantitative reverse transcription-polymerase chain reaction. Pediatr. Res. 1994, 35, 179–183. [CrossRef] [PubMed]

40. Truong, D.; Minich, L.; Lin, E.; Williams, R.V.; Schlaberg, R.; Lambert, L.M.; Yang, Y.; Areinamo, I.; Ampofo, K.; Tristani-Firouzi, M. Next Generation Sequencing in Kawasaki Disease: A Pilot Study. Circulation 2019, 140, A15274. [CrossRef]

41. Horinouchi, T.; Nozu, K.; Hamahira, K.; Inaguma, Y.; Abe, J.; Nakajima, H.; Kugo, M.; Iijima, K. Yersinia pseudotuberculosis patients with Kawasaki disease. J. Inflamm. (Lond) 2020, 18, 1345–1357. [CrossRef]

42. Chen, M.R.; Kuo, H.C.; Lee, Y.J.; Chi, H.; Li, S.C.; Lee, H.C.; Yang, K.D. Phenotype, Susceptibility, Autoimmunity, and Immunotherapy Between Kawasaki Disease and Coronavirus Disease-19 Associated Multisystem Inflammatory Syndrome in Children. Front. Immunol. 2021, 12, 632890. [CrossRef]

43. Jorgensen, I.; Miao, E.A. Pyroptotic cell death defends against intracellular pathogens. Immuno. Rev. 2015, 265, 130–142. [CrossRef]

44. Evans, P.C.; Rainger, G.E.; Mason, J.C.; Guzik, T.J.; Osto, E.; Stamataki, Z.; Neil, D.; Hoefer, I.E.; Fragiadaki, M.; Waltenberger, J.; et al. Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. Cardiovasc. Res. 2020, 116, 2177–2184. [CrossRef] [PubMed]

45. Barnett, K.C.; Kagan, J.C. Lipids that directly regulate innate immune signal transduction. Innate. Immun. 2020, 26, 4–14. [CrossRef]

46. He, Y.; Qiu, H.X.; Wu, R.Z.; Rong, X.; Xu, H.T.; Xiang, R.L.; Chu, M.P. Oxidised Low-Density Lipoprotein and Its Receptor-Mediated Endothelial Dysfunction Are Associated with Coronary Artery Lesions in Kawasaki Disease. J. Cardiovasc. Transl. Res. 2020, 13, 204–214. [CrossRef]

47. Zeng, C.; Wang, R.; Tan, H. Role of Pyroptosis in Cardiovascular Diseases and its Therapeutic Implications. Int. J. Biol. Sci. 2019, 15, 1345–1357. [CrossRef]

48. Tang, J.; Zhang, Y.; Zhang, X.; Liao, Y.; Wang, Y.; Ouyang, S.; Che, Y.; Xu, M.; Pu, J.; Shen, Q.; et al. RNA gene profile variation in peripheral blood mononuclear cells from rhesus macaques immunized with Hib conjugate vaccine, Hib capsular polysaccharide and TT carrier protein. BMC Immunol. 2018, 19, 4. [CrossRef] [PubMed]

49. Antas, P.R.Z.; Ponte, C.G.G.; Almeida, M.R.; Albuquerque, L.H.P.; Sousa-Vasconcelos, P.S.; Pedro, T.; Gomes, N.L.S.; Moreira, O.C.; Silva, F.C.; Castello-Branco, L.R.R.; et al. The in vitro Mycobacterium bovis BCG Moreau infection of human monocytes that induces Caspase-1 expression, release and dependent cell death is mostly reliant upon cell integrity. J. Inflamm. (Lond) 2019, 16, 18. [CrossRef]

50. Ponte, C.; Hacker, M.; Moraes, M.; Castello-Branco, L.; Silva, F.; Antas, P. The patterns of in vitro cell-death and inflammatory cytokines induced by distinct BCG vaccine strains are differentially induced in human mononuclear cells. Hum. Vaccines Immunother. 2018, 14, 28–35. [CrossRef] [PubMed]
51. HogenEsch, H.; O’Hagan, D.T.; Fox, C.B. Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. *NPJ Vaccines* **2018**, *3*, 51. [CrossRef]

52. Hara, T.; Yamamura, K.; Sakai, Y. The up-to-date pathophysiology of Kawasaki disease. *Clin. Transl. Immunol.* **2021**, *10*, e1284. [CrossRef]